Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 415

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

The Age-related Eye Disease Study 2 (AREDS2)

Open access
Chew, Emily Y., Clemons, Traci, SanGiovanni, John Paul, Danis, Ronald, Domalpally, Amitha, McBee, Wendy, Sperduto, Robert, Ferris, Frederick L. · 2012 · Ophthalmology

Abstract

Purpose The Age-Related Eye Disease Study (AREDS) demonstrated beneficial effects of oral supplementation with antioxidant vitamins and minerals on the development of advanced age-related macular degeneration (AMD) in persons with at least intermediate AMD (bilateral large drusen with or without pigment changes). Observational data suggest that other oral nutrient supplements might further reduce the risk of progression to advanced AMD. The primary purpose of Age-Related Eye Disease Study 2 (AREDS2) is to evaluate the efficacy and safety of lutein+zeaxanthin (L+Z) and/or omega-3 long-chain polyunsaturated fatty acid (LCPUFA) supplementation in reducing the risk of developing advanced AMD. The study will also assess the reduction in zinc and the omission of beta-carotene from original AREDS formulation. Design Multicenter phase 3 randomized controlled clinical trial Participants Persons age 50 to 85 with bilateral intermediate AMD or advanced AMD in one eye Methods All participants were randomly assigned to: 1) placebo (n=1012); 2) L+Z (10 mg/2 mg, n=1044); 3) ω-3 LCPUFAs (eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) [650gmg/350 mg] n=1069); or 4) the combination of L+Z and ω -3 LCPUFAs (n=1078). All participants were offered a secondary randomization to 1 of 4 variations of the original AREDS formulation keeping vitamins C (500 mg), E (400 IU), and copper (2 mg) unchanged while varying zinc and beta-carotene as follows: zinc remains at the original level (80mg), lower only zinc to 25mg, omit beta-carotene only, or lower zinc to 25 mg and omit beta-carotene. Main Outcome Measures Progression to advanced AMD determined by centralized grading of annual fundus photographs. Results 4,203 participants were enrolled at 82 clinical centers located in the U.S. Population characteristics at baseline were as follows: mean age 74 years, 57% female, 97% white, 7% current smokers, 19% with prior cardiovascular disease and 44% and 50% taking statin-class cholesterol lowering drugs and aspirin, respectively. Ocular characteristics include 59% with bilateral large drusen, 32% with advanced AMD in one eye and mean visual acuity of 20/32 in eyes without advanced AMD. Conclusion This report presents the AREDS2 study design and the participants’ baseline demographic and ocular characteristics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ophtha.2012.05.027

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

See all 415

Metadata

Authors
Chew, E. Y., Clemons, T., SanGiovanni, J. P., Danis, R., Domalpally, A., McBee, W., Sperduto, R., & Ferris, F. L.
Venue
Ophthalmology
Publisher
Elsevier BV
Published
2012-11
Volume
119
Issue
11
Pages
2282-2289
ISSN
0161-6420 (ISSN-L)
OpenAlex
W2154864949
Cited by
415
References
43
FWCI
19.14
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Age-related Eye Disease Study 2 (AREDS2). https://app.cochat.ai/papers/10.1016/j.ophtha.2012.05.027
The paper
Chew, E. Y., Clemons, T., SanGiovanni, J. P., Danis, R., Domalpally, A., McBee, W., Sperduto, R., & Ferris, F. L. (2012). The Age-related Eye Disease Study 2 (AREDS2). Ophthalmology. https://doi.org/10.1016/j.ophtha.2012.05.027

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.